ALK and non-small cell lung carcinoma: Amongst the potentially actionable genes not expressed or expressed at low levels, were ALK and RET. The ALK gene is translocated in 3–5% of patients with NSCLC and is a validated target for at least five approved therapeutics for this malignancy, i.e., crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib [97].